YTHDC2

Across TCGA pan-cancer cohorts, YTHDC2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of YTHDC2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where YTHDC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types YTHDC2 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRC, THCA, and LIHC are the cancer types where YTHDC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in YTHDC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.689	<.001	11	view →
THCA	All	All	−0.375	<.001	9	view →
LIHC	All	All	+0.415	<.001	7	view →
BRCA	All	II,III,IV	+0.273	.004	6	view →
CHOL	All	All	+1.166	<.001	3	view →
KICH	All	All	−0.489	.010	2	view →
UCEC	All	IV	−0.399	.040	2	view →
PRAD	All	All	+0.319	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

YTHDC2–KIRC

Open the KIRC breakdown →